Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline
An international panel including two patient partners, clinicians, and methodologists produced these recommendations. The panel followed standards for trustworthy guidelines and used the GRADE approach, explicitly considering the balance of benefits, harms and burdens of treatment from an individual patient perspective. Recommendations were informed by a linked living systematic review and network meta-analysis evaluating relative benefits and harms updated to 31 July 2024; and by linked systematic reviews addressing risk prediction models and values and preferences of adults with type 2 diabetes. Candidate therapeutics are prioritised based on availability of sufficient randomised trial data, relevance to a global audience and likelihood of changing practice.This is the first version of the living guideline. The guideline is part of the <i>BMJ Rapid Recommendations</i> series. MAGICapp displays the most recent version of the guideline and full content including evidence summaries and decision aids; major updates will be published in <i>The BMJ</i>. We encourage re-use, adaptation and translation of these living guidelines, and recognise that the lack of availability or high costs of some medications may be prohibitive and will impact on how these recommendations are implemented across different health care systems.
Authors
- Thomas Agoritsas (ORCID: https://orcid.org/0000-0002-6182-9969)
- Per Olav Vandvik (ORCID: https://orcid.org/0000-0001-8958-2710)
- Arnav Agarwal (ORCID: https://orcid.org/0000-0002-0931-7851)
- Mieke Vermandere (ORCID: https://orcid.org/0000-0002-0437-6633)
- Veena Manja (ORCID: https://orcid.org/0000-0003-0410-8089)
- Evi Nagler
- Gordon Guyatt (ORCID: https://orcid.org/0000-0003-2352-5718)
- René Rodríguez‐Gutiérrez (ORCID: https://orcid.org/0000-0002-3022-5302)
- Vivekanand Jha (ORCID: https://orcid.org/0000-0002-8015-9470)
- Daniel Rayner (ORCID: https://orcid.org/0000-0001-6699-3090)
- Adrienne Odom
- Farid Foroutan (ORCID: https://orcid.org/0000-0002-1029-1812)
- Reem A. Mustafa (ORCID: https://orcid.org/0000-0002-2091-0875)
- Bjørn Olav Åsvold (ORCID: https://orcid.org/0000-0003-3837-2101)
- Robin Wright
- Helen MacDonald
- Jenan Gabi
- Anja Fog Heen (ORCID: https://orcid.org/0000-0002-8873-7028)
- Lixin Guo (ORCID: https://orcid.org/0000-0003-2609-8387)
- Sheyu Li (ORCID: https://orcid.org/0000-0003-0060-0287)
- Qiukui Hao (ORCID: https://orcid.org/0000-0002-5160-5144)
- Sahana Shetty (ORCID: https://orcid.org/0000-0003-0851-0411)
- Nicolas Rodondi
- Britta Tendel Jeppesen
Institutions
- University of Geneva (CH)
- University of Bern (CH)
- University of Alberta (CA)
- Manipal Academy of Higher Education (IN)
- Universidad Autónoma de Nuevo León (MX)
- An-Najah National University (PS)
- University of Oslo (NO)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Norwegian University of Science and Technology (NO)
- Sichuan University (CN)
- University Hospital of Bern (CH)
- Ghent University Hospital (BE)
- West China Hospital of Sichuan University (CN)
- Ted Rogers Centre for Heart Research (CA)
- Lovisenberg Diakonale Høgskole (NO)
- St Olav's University Hospital (NO)
- Hospital Universitario Dr José Eleuterio Gonzalez (MX)
- Hypertension Institute (US)
- Pour la Solidarité (BE)
- George Institute for Global Health (IN)
- Mayo Clinic in Florida (US)
- Impact (CA)
- Imperial College London (GB)
- British Medical Association (GB)
- University of California, Davis (US)
- National Patient Safety Foundation (US)
- Sirris (BE)
Publication Details
- Journal
- BMJ
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1136/bmj-2024-082071
- Citations
- 12
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 15.54